Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis ...

Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the two pivotal Phase 3 randomized, ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Extends Pediatric Psoriasis Study: What ...

A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...

Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...

Takeda reports positive Phase 3 data for psoriasis drug zasocitinib, beating placebo and Otezla, with rapid PASI responses ...

Early Thursday, Takeda revealed top-line data for two pivotal phase 3 trials of its next-gen, highly selective oral tyrosine ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

Emirates Drug Establishment Approves Tapinarof Cream 1%, A New Treatment For Plaque Psoriasis In Adults And Atopic Dermatitis ...